G01N33/6842

Nanoparticle probes and methods of making and use thereof
10507253 · 2019-12-17 ·

Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Methods for liquid chromatography calibration for rapid labeled N-glycans

Methods are provided for making rapid labeled dextran ladders and other calibrants useful in liquid chromatography. The methodologies include a two-step process comprising a reductive amination step of providing a reducing glycan and reacting it with a compound having a primary amine to produce an intermediate compound. The intermediate compound is then rapidly tagged with a rapid tagging reagent to produce the rapid labeled dextran ladder.

MOLECULAR KINETICS EVALUATION METHOD AND SCREENING METHOD

A molecular kinetics evaluation method is provided which involves: a step for dosing a human or non-human animal with a proteolysis-inducing molecule, which is a conjugate of a proteolysis induction tag, i.e., a molecule which has affinity for protease and which does not inhibit proteolysis by protease, and a specific protein affinity molecule having affinity to a specific protein, and inducing proteolysis of the specific protein in vivo in the human or non-human animal; and a step for evaluating the molecular kinetics of the specific protein affinity molecules or the proteolysis-inducing molecules by detecting proteolysis of the specific proteins in a sample which is at least part of the human or non-human animal.

METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

IDENTIFICATION, QUANTITATION AND ANALYSIS OF UNIQUE BIOMARKERS IN SWEAT

A biomarker diagnostic system includes a sensor to collect a sweat sample from a biological subject; a processor operatively connected to the sensor, wherein the processor is configured to perform metabolic and proteomic profiling of biomarkers in the sweat sample. The metabolic and proteomic profile is compared to a predetermined profile of the biomarkers and to determine a physiological status of the biomarkers. The system further includes a feedback unit operatively coupled to the sensor and the processor and configured to output physiological performance data based on the physiological status.

Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis

Disclosed herein are formulations, substrates, and arrays. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays, including porous arrays. Also disclosed herein are formulations and methods for one-step coupling, e.g., for synthesis of peptides in an N->C orientation. In some embodiments, disclosed herein are formulations and methods for high efficiency coupling of biomolecules to a substrate.

SENSORS AND ASSAYS FOR UBIQUITIN OR UBIQUITIN-LIKE PROTEINS
20190346453 · 2019-11-14 ·

The present invention provides compositions comprising chimeric polypeptides that bind to free ubiquitin proteins or free ubiquitin-like proteins with high affinity, as well as chimeric polypeptides that bind to both free and conjugated ubiquitin proteins or free and conjugated ubiquitin-like proteins, and methods of using the chimeric polypeptides to determine the amount of free or total ubiquitin or free or total ubiquitin-like proteins in various types of samples.

Lipid Nanodisc formation by Acryloyl-based copolymers

The disclosure generally relates generally to lipid nanodiscs, in particular to lipid nanodiscs formed from acryloyl-based copolymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and an acryloyl-based copolymer encircling the hydrophobic edge of the lipid bilayer. The acryloyl-based copolymer includes a first monomer unit having a pendant hydrophobic group and a second monomer unit having a pendant hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

Methods apparatuses and systems for detecting and quantifying phosphoproteins

Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics.

METHODS OF DETECTING GLYCOSAMINOGLYCANS
20190339236 · 2019-11-07 ·

In one aspect, the disclosure provides methods of distinguishing a glycosaminoglycan from one or more other components in a sample by subjecting the sample to size-exclusion chromatography using a mobile phase having a pH of 6.8 or lower. A mobile phase having a pH of 6.8 or lower is found to improve the separation of glycosaminoglycans from proteins during size exclusion chromatography. In some embodiments, improved separation is due to the low pH of the mobile phase causing elution of less dispersed fractions of the protein and/or glycosaminoglycan. In some embodiments, the overlap between protein and/or glycosaminoglycan fractions is reduced.